Variant position: 152 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 400 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human MGTWPFGTILCKIVISIDYY NMFTSIFTLCTMSVDRYIAVC
Rhesus macaque MGTWPFGTILCKIVISIDYY NMSTSIFTLCTMSVDRYIAVC
Chimpanzee MGTWPFGTILCKIVISIDYY NMFTSIFTLCTMSVDRYIAVC
Mouse MGTWPFGNILCKIVISIDYY NMFTSIFTLCTMSVDRYIAVC
Rat MGTWPFGTILCKIVISIDYY NMFTSIFTLCTMSVDRYIAVC
Pig MGTWPFGTILCKIVISIDYY NMFTSIFTLCTMSVDRYIAVC
Bovine MGTWPFGTILCKIVISIDYY NMFTSIFTLCTMSVDRYIAVC
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 400 Mu-type opioid receptor
143 – 165 Helical; Name=3
168 – 168 Phosphotyrosine
142 – 219
97 – 400 RYTKMKTATNIYIFNLALADALATSTLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDFRTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHIYVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP -> SSSWF. In isoform 17.
98 – 400 YTKMKTATNIYIFNLALADALATSTLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDFRTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHIYVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP -> YSWFVIGGPEGRRKQRRLGEDKRARGCGEKG. In isoform 16.
98 – 186 YTKMKTATNIYIFNLALADALATSTLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDFRTPRNA -> FHRLYTNILSSNLVLGKPAEDLCFHLRLHYASAHHYRVLWTDDLAPQECPHALWLQRKGQESSKDHQDGAGGGGCVHRLLDSHSHLRHH. In isoform 18.
142 – 142 C -> AS. Abolishes ligand binding; when associated with A-219 or S-219.
NIEHS SNPs program;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS VAL-6; ASP-40; CYS-147; ASP-152; CYS-265 AND ASN-274;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.